{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:18:03Z","timestamp":1780985883499,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Reberg's Trust for Parkinson Research"},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Impaired impulse control is often seen in Parkinson\u2019s disease (PD) patients using dopamine agonists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed a therapeutic drug monitoring study of 100 PD patients using ropinirole or pramipexole extended release. Three blood samples were collected on the same day. Serum concentrations were measured, and 24\u00a0h area under the curve (AUC) calculated. The validated Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) was used for assessing impulse control.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Total ropinirole drug exposure showed weak, but significant correlation to the QUIP-RS score. No correlation between pramipexole serum concentrations and QUIP-RS was found. In ropinirole patients, both agonist dose and total dopaminergic treatment were correlated with QUIP-RS. Duration of ropinirole treatment correlated with impaired impulse control, and duration of dopaminergic treatment of any type correlated with QUIP-RS scores in both ropinirole and pramipexole patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our main finding is that impaired impulse control is correlated to both total drug exposure (AUC) and dopamine agonist dose for ropinirole, but not for pramipexole. These observations indicate that different strategies may be useful for treating PD patients with impaired impulse control: ropinirole dose reduction could be beneficial, whereas pramipexole treatment may have to be stopped.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-024-12870-8","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T13:36:09Z","timestamp":1736948169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impulse control and correlation to dopamine agonist serum concentrations in people with Parkinson's disease"],"prefix":"10.1007","volume":"272","author":[{"given":"Sara C.","family":"Staubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Martin","family":"Fuskev\u00e5g","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Toft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg H.","family":"Lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsti M. J.","family":"Alvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Jostad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein H.","family":"Tingvoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallvard","family":"Lilleng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Rosqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"St\u00f8rset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3328-5263","authenticated-orcid":false,"given":"Espen","family":"Dietrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Sveberg","family":"Dietrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"12870_CR1","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/nejm200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484\u20131491. https:\/\/doi.org\/10.1056\/nejm200005183422004","journal-title":"N Engl J Med"},{"key":"12870_CR2","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Fahn S et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044. https:\/\/doi.org\/10.1001\/archneur.61.7.1044","journal-title":"Arch Neurol"},{"key":"12870_CR3","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/mds.21110","volume":"21","author":"KA Grosset","year":"2006","unstructured":"Grosset KA, Macphee G, Pal G et al (2006) Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord 21:2206\u20132208. https:\/\/doi.org\/10.1002\/mds.21110","journal-title":"Mov Disord"},{"key":"12870_CR4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1212\/01.wnl.0000238503.20816.13","volume":"67","author":"V Voon","year":"2006","unstructured":"Voon V, Hassan K, Zurowski M et al (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67:1254\u20131257","journal-title":"Neurology"},{"key":"12870_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/0269881106073109","volume":"21","author":"N Giladi","year":"2007","unstructured":"Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C (2007) New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson\u2019s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 21:501\u2013506. https:\/\/doi.org\/10.1177\/0269881106073109","journal-title":"J Psychopharmacol"},{"key":"12870_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archneur.63.7.969","volume":"63","author":"D Weintraub","year":"2006","unstructured":"Weintraub D, Siderowf AD, Potenza MN et al (2006) Dopamine agonist use is associated with impulse control disorders in Parkinson disease. Arch Neurol 63:969\u2013973. https:\/\/doi.org\/10.1001\/archneur.63.7.969","journal-title":"Arch Neurol"},{"key":"12870_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN et al (2010) Impulse Control Disorders in Parkinson Disease: a cross-sectional study. Arch Neurol 67:589\u2013595. https:\/\/doi.org\/10.1001\/archneurol.2010.65","journal-title":"Arch Neurol"},{"key":"12870_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A et al (2014) Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85:840\u2013844. https:\/\/doi.org\/10.1136\/jnnp-2013-306787","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12870_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/jnnp-2016-315277","volume":"88","author":"A Antonini","year":"2017","unstructured":"Antonini A, Barone P, Bonuccelli U et al (2017) ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 88:317\u2013324. https:\/\/doi.org\/10.1136\/jnnp-2016-315277","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12870_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.578924","volume":"11","author":"S Binck","year":"2020","unstructured":"Binck S, Pauly C, Vaillant M, Binck S, et al. et al (2020) Contributing factors and evolution of impulse control disorder in the luxembourg Parkinson cohort. Front Neurol 11:578924. https:\/\/doi.org\/10.3389\/fneur.2020.578924","journal-title":"Front Neurol"},{"key":"12870_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, David AS, Evans AH, Grant JE, Stacy M (2015) Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov Disord 30:121\u2013127. https:\/\/doi.org\/10.1002\/mds.26016","journal-title":"Mov Disord"},{"key":"12870_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1212\/01.wnl.0000076478.45005.ec","volume":"61","author":"E Driver-Dunckley","year":"2003","unstructured":"Driver-Dunckley E, Samanta J, Stacy M (2003) Pathological gambling associated with dopamine agonist therapy in Parkinson\u2019s disease. Neurology 61:422\u2013423. https:\/\/doi.org\/10.1212\/01.wnl.0000076478.45005.ec","journal-title":"Neurology"},{"key":"12870_CR13","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","volume":"62","author":"ML Dodd","year":"2005","unstructured":"Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE (2005) Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62:1377\u20131381. https:\/\/doi.org\/10.1001\/archneur.62.9.noc50009","journal-title":"Arch Neurol"},{"key":"12870_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","volume":"11","author":"KJ Klos","year":"2005","unstructured":"Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE (2005) Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson\u2019s disease and multiple system atrophy. Parkinsonism Relat Disord 11:381\u2013386. https:\/\/doi.org\/10.1016\/j.parkreldis.2005.06.005","journal-title":"Parkinsonism Relat Disord"},{"key":"12870_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/mds.24023","volume":"27","author":"D Weintraub","year":"2012","unstructured":"Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A (2012) Questionnaire for impulsive-compulsive disorders in Parkinson\u2019s Disease-Rating Scale. Mov Disord 27:242\u2013247. https:\/\/doi.org\/10.1002\/mds.24023","journal-title":"Mov Disord"},{"key":"12870_CR16","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/mds.27181","volume":"32","author":"R Biundo","year":"2017","unstructured":"Biundo R, Weis L, Abbruzzese G et al (2017) Impulse control disorders in advanced Parkinson\u2019s disease with dyskinesia: The ALTHEA study. Mov Disord 32:1557\u20131565. https:\/\/doi.org\/10.1002\/mds.27181","journal-title":"Mov Disord"},{"key":"12870_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41598-020-73756-z","volume":"10","author":"S Jes\u00fas","year":"2020","unstructured":"Jes\u00fas S, Labrador-Espinosa MA, Adarmes AD et al (2020) Non-motor symptom burden in patients with Parkinson\u2019s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. Sci Rep 10:1038. https:\/\/doi.org\/10.1038\/s41598-020-73756-z","journal-title":"Sci Rep"},{"key":"12870_CR18","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1212\/wnl.0000000000005816","volume":"91","author":"J-C Corvol","year":"2018","unstructured":"Corvol J-C, Artaud F, Cormier-Dequaire F et al (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91:e189\u2013e201. https:\/\/doi.org\/10.1212\/wnl.0000000000005816","journal-title":"Neurology"},{"key":"12870_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mds.25291","volume":"28","author":"J Bastiaens","year":"2013","unstructured":"Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ (2013) Prospective cohort study of impulse control disorders in Parkinson\u2019s disease. Mov Disord 28:327\u2013333. https:\/\/doi.org\/10.1002\/mds.25291","journal-title":"Mov Disord"},{"key":"12870_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/ene.13034","volume":"23","author":"A Rizos","year":"2016","unstructured":"Rizos A, Sauerbier A, Antonini A et al (2016) A European multicentre survey of impulse control behaviours in Parkinson\u2019s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 23:1255\u20131261. https:\/\/doi.org\/10.1111\/ene.13034","journal-title":"Eur J Neurol"},{"key":"12870_CR21","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/healthcare9101263","volume":"9","author":"MI Garc\u00eda-Rubio","year":"2021","unstructured":"Garc\u00eda-Rubio MI, Otero-Cerdeira ME, Toledo-Lozano CG et al (2021) Analysis of Impulse Control Disorders (ICDs) and Factors Associated with Their Development in a Parkinson\u2019s Disease Population. Healthcare 9:1263. https:\/\/doi.org\/10.3390\/healthcare9101263","journal-title":"Healthcare"},{"key":"12870_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10072-023-07006-1","volume":"45","author":"A Gunduz","year":"2024","unstructured":"Gunduz A, \u00c7ift\u00e7i T, Erbil AC, Senoglu G, Ser MH, Apayd\u0131n H (2024) Impulse control disorders in Parkinson\u2019s disease: a retrospective analysis of 1824 patients in a 12-year period. Neurol Sci 45:171\u2013175. https:\/\/doi.org\/10.1007\/s10072-023-07006-1","journal-title":"Neurol Sci"},{"key":"12870_CR23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/ana.22356","volume":"69","author":"V Voon","year":"2011","unstructured":"Voon V, Sohr M, Lang AE et al (2011) Impulse control disorders in Parkinson disease: a multicenter case\u2013control study. Ann Neurol 69:986\u2013996. https:\/\/doi.org\/10.1002\/ana.22356","journal-title":"Ann Neurol"},{"key":"12870_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.parkreldis.2012.06.005","volume":"18","author":"J Joutsa","year":"2012","unstructured":"Joutsa J, Martikainen K, Vahlberg T, Kaasinen V (2012) Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson\u2019s disease. Parkinsonism Relat Disord 18:1079\u20131083. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.06.005","journal-title":"Parkinsonism Relat Disord"},{"key":"12870_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","volume":"35","author":"S Perez-Lloret","year":"2012","unstructured":"Perez-Lloret S, Rey MV, Fabre N et al (2012) Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol 35:261\u2013265. https:\/\/doi.org\/10.1097\/WNF.0b013e31826e6e6d","journal-title":"Clin Neuropharmacol"},{"key":"12870_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/JCP.0b013e3182979830","volume":"33","author":"M Poletti","year":"2013","unstructured":"Poletti M, Logi C, Lucetti C et al (2013) A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol 33:691\u2013694. https:\/\/doi.org\/10.1097\/JCP.0b013e3182979830","journal-title":"J Clin Psychopharmacol"},{"key":"12870_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/s-2007-1017459","volume":"16","author":"HP Vogel","year":"1983","unstructured":"Vogel HP, Schiffter R (1983) Hypersexuality-a complication of dopaminergic therapy in Parkinson\u2019s disease. Pharmacopsychiatria 16:107\u2013110. https:\/\/doi.org\/10.1055\/s-2007-1017459","journal-title":"Pharmacopsychiatria"},{"key":"12870_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00002826-198910000-00002","volume":"12","author":"RJ Uitti","year":"1989","unstructured":"Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B (1989) Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12:375\u2013383. https:\/\/doi.org\/10.1097\/00002826-198910000-00002","journal-title":"Clin Neuropharmacol"},{"key":"12870_CR29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/1531-8257(200009)15:5<869::aid-mds1016>3.0.co;2-i","volume":"15","author":"JA Molina","year":"2000","unstructured":"Molina JA, Sainz-Artiga MJ, Fraile A et al (2000) Pathologic gambling in Parkinson\u2019s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 15:869\u2013872. https:\/\/doi.org\/10.1002\/1531-8257(200009)15:5%3c869::aid-mds1016%3e3.0.co;2-i","journal-title":"Mov Disord"},{"key":"12870_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10072-022-06485-y","volume":"44","author":"M Contin","year":"2023","unstructured":"Contin M, Lopane G, Marini L et al (2023) Screening for impulse control disorders in Parkinson\u2019s disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors. Neurol Sci 44:565\u2013572. https:\/\/doi.org\/10.1007\/s10072-022-06485-y","journal-title":"Neurol Sci"},{"key":"12870_CR31","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s10072-023-07254-1","volume":"45","author":"LG Soileau","year":"2024","unstructured":"Soileau LG, Talbot NC, Storey NR et al (2024) Impulse control disorders in Parkinson\u2019s disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis. Neurol Sci 45:1399\u20131408. https:\/\/doi.org\/10.1007\/s10072-023-07254-1","journal-title":"Neurol Sci"},{"key":"12870_CR32","doi-asserted-by":"publisher","first-page":"16144","DOI":"10.1111\/ene.16144","volume":"31","author":"SC Staubo","year":"2024","unstructured":"Staubo SC, Fuskev\u00e5g OM, Toft M et al (2024) Dopamine agonist serum concentrations and impulse control disorders in Parkinson\u2019s disease. Eur J Neurol 31:16144. https:\/\/doi.org\/10.1111\/ene.16144","journal-title":"Eur J Neurol"},{"key":"12870_CR33","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30:1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"12870_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/ene.12646","volume":"22","author":"H Baumann-Vogel","year":"2015","unstructured":"Baumann-Vogel H, Valko PO, Eisele G, Baumann CR (2015) Impulse control disorders in Parkinson\u2019s disease: don\u2019t set your mind at rest by self-assessments. Eur J Neurol 22:603\u2013609. https:\/\/doi.org\/10.1111\/ene.12646","journal-title":"Eur J Neurol"},{"key":"12870_CR35","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1002\/mds.21696","volume":"22","author":"M Visser","year":"2007","unstructured":"Visser M, Verbaan D, van Rooden SM, Stiggelbout AM, Marinus J, van Hilten JJ (2007) Assessment of psychiatric complications in Parkinson\u2019s disease: The SCOPA-PC. Mov Disord 22:2221\u20132228. https:\/\/doi.org\/10.1002\/mds.21696","journal-title":"Mov Disord"},{"key":"12870_CR36","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170","journal-title":"Mov Disord"},{"key":"12870_CR37","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.22340","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19:1020\u20131028. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"key":"12870_CR38","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25:2649\u20132653. https:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"key":"12870_CR39","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AH et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord 21:916\u2013923. https:\/\/doi.org\/10.1002\/mds.20844","journal-title":"Mov Disord"},{"key":"12870_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease. Qual Life Res 4:241\u2013248. https:\/\/doi.org\/10.1007\/BF02260863","journal-title":"Qual Life Res"},{"key":"12870_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","volume":"39","author":"CM Kaye","year":"2000","unstructured":"Kaye CM, Nicholls B (2000) Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 39:243\u2013254. https:\/\/doi.org\/10.2165\/00003088-200039040-00001","journal-title":"Clin Pharmacokinet"},{"key":"12870_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5664\/jcsm.27239","volume":"4","author":"TM Juergens","year":"2008","unstructured":"Juergens TM (2008) Adverse effects of ropinirole-treated restless leg syndrome (RLS) during smoking cessation. J Clin Sleep Med 4:371\u2013372","journal-title":"J Clin Sleep Med"},{"key":"12870_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mds.29700","volume":"39","author":"I Debove","year":"2024","unstructured":"Debove I, Paschen S, Amstutz D et al (2024) Management of impulse control and related disorders in parkinson\u2019s disease: an expert consensus. Mov Disord 39:235\u2013248. https:\/\/doi.org\/10.1002\/mds.29700","journal-title":"Mov Disord"},{"key":"12870_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102259","volume":"27","author":"H Sparks","year":"2020","unstructured":"Sparks H, Riskin-Jones H, Price C et al (2020) Impulsivity relates to relative preservation of mesolimbic connectivity in patients with Parkinson disease. Neuroimage Clin 27:102259. https:\/\/doi.org\/10.1016\/j.nicl.2020.102259","journal-title":"Neuroimage Clin"},{"key":"12870_CR45","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1186\/s42466-019-0013-5","volume":"1","author":"M B\u00e9reau","year":"2019","unstructured":"B\u00e9reau M, Krack P, Br\u00fcggemann N, M\u00fcnte TF (2019) Neurobiology and clinical features of impulse control failure in Parkinson\u2019s disease. Neurol Res Pract 1:1186. https:\/\/doi.org\/10.1186\/s42466-019-0013-5","journal-title":"Neurol Res Pract"},{"key":"12870_CR46","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3233\/JPD-150535","volume":"5","author":"M Sierra","year":"2015","unstructured":"Sierra M, Carnicella S, Strafella AP et al (2015) Apathy and impulse control disorders: Yin & Yang of dopamine dependent behaviors. J Parkinsons Dis 5:625\u2013636. https:\/\/doi.org\/10.3233\/JPD-150535","journal-title":"J Parkinsons Dis"},{"key":"12870_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/ana.26164","volume":"90","author":"D Weiss","year":"2021","unstructured":"Weiss D, Volkmann J, Fasano A, K\u00fchn A, Krack P, Deuschl G (2021) Changing gears \u2013 DBS for dopaminergic desensitization in Parkinson\u2019s disease?. Ann Neurol 90:699\u2013710. https:\/\/doi.org\/10.1002\/ana.26164","journal-title":"Ann Neurol"},{"key":"12870_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.01.113","volume":"58","author":"LE De Wit","year":"2022","unstructured":"De Wit LE, Wilting I, Souverein PC, Van Der Pol P, Egberts TCG (2022) Impulse control disorders associated with dopaminergic drugs: a disproportionality analysis using vigibase. Eur Neuropsychopharmacol 58:30\u201338. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.01.113","journal-title":"Eur Neuropsychopharmacol"},{"key":"12870_CR49","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1162\/jocn_a_00946","volume":"28","author":"HJ Macdonald","year":"2016","unstructured":"Macdonald HJ, Stinear CM, Ren A et al (2016) Dopamine gene profiling to predict impulse control and effects of dopamine agonist ropinirole. J Cogn Neurosci 28:909\u2013919. https:\/\/doi.org\/10.1162\/jocn_a_00946","journal-title":"J Cogn Neurosci"},{"key":"12870_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2021.100113","volume":"5","author":"A Hall","year":"2021","unstructured":"Hall A, Weaver SR, Compton LJ, Byblow WD, Jenkinson N, MacDonald HJ (2021) Dopamine genetic risk score predicts impulse control behaviors in Parkinson\u2019s disease. Clin Park Relat Disord 5:100113. https:\/\/doi.org\/10.1016\/j.prdoa.2021.100113","journal-title":"Clin Park Relat Disord"},{"key":"12870_CR51","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1365-2125.2011.04023.x","volume":"72","author":"J Hukkanen","year":"2011","unstructured":"Hukkanen J, Jacob P, Peng M, Dempsey D, Benowitz NL (2011) Effect of nicotine on cytochrome P450 1A2 activity. Br J Clin Pharmacol 72:836\u2013838. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04023.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12870-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:41:16Z","timestamp":1739637676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12870-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["12870"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12870-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no financial or non-financial competing interests related to this study. Not related to this study: Per Odin has given lectures and\/or been advisor with honorarium for AbbVie, Bial, Britannia, Global Kinetics, Lobsor, Lundbeck, Nordic Infucare, Stada, UCB and Zambon, and has participated as an investigator in clinical studies performed by AbbVie, Global Kinetics, IRL, UCB and Zambon. Espen Dietrichs has given lectures and\/or been advisor with honorarium for AbbVie, Global Kinetics, Ipsen and Nordic Infucare. The other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Personvernombudet\/Datatilsynet (General Data Protection Regulation in Norway; reference: 2018\/6255), the Regional Ethical Committee in Northern Norway (reference: 2018\/1343\/REK nord), and the Swedish Ethical Board (reference: 2022\u201301340-01). Written informed consent was obtained from each study participant before inclusion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"134"}}